Efficacy and safety of cadonilimab, an anti-PD1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: A multicenter, openlabel, single-arm, phase II trial (89). This evidence concerns the gene CTLA4 and cervical cancer.